Fast Facts

About King Pharmaceuticals Canada, Inc.

King Pharmaceuticals, Inc. established King Pharmaceuticals Canada in 2006 with the goal of applying our resources and capabilities to help meet Canada's healthcare needs. Our Canadian presence provides a unique opportunity to better understand the local healthcare environment so that we may continuously help improve the wellbeing of Canadians.

King Pharmaceuticals Canada is heaquartered in the Canadian pharmaceutical hub of Mississauga, Ontario, Canada. This location provides us with a central location for distributing and selling pharmaceutical products throughout Canada.

Canadian Operations - Mississauga, Ontario, Canada

Key Products

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.

President and CEO - Brian Markison

Year Founded - January 1994

Stock Exchange Listing - NYSE (KG)

Corporate Headquarters - Bristol, Tennessee

Commercial Operations - Bridgewater, NJ

Manufacturing

Bristol, TN
Rochester, MI
St. Louis, MO
St. Petersburg, FL
Middleton, WI

Research & Development

Cary, NC

Meridian Medical Technologies

Columbia, MD

Website Address - www.kingpharm.com

Employees - 2,900

Sales Force - 1,100+

Recognition

Top 9 Best Managed Drug Companies by Fortune - January 2006
No. 39 on Pharmaceutical Executive's 2007 Top 50 Pharma Companies list

Key Products

Altace^®
Skelaxin^®
Thrombin-JMI^®
Avinza^®
Sonata^®
Levoxyl^®
Meridian Emergency Products
EpiPen^®

R&D Pipeline

Late Stage

Remoxy™
Vanquix^®
binodenoson

Early to Mid Stage

Bremelanotide
MRE0094
T-62

Product/Line Extensions

Altace®/HCT combination
Altace^® TOPHAT - Pediatric
Altace^® Nephropathy

Core Competencies

Commercialization and marketing: 1,100+ member sales force in the U.S., Canada and Puerto Rico, with strengths in cardiovascular/metabolics, neuroscience and hospital/acute care.
Research and development: Approximately 100 research and development employees specializing in core R&D, pharmacovigilance, clinical operation, regulatory affairs, medical affairs and project management.
Business development
Manufacturing and quality control: produce a broad array of dosage forms including tablets, capsules, liquids, suspensions, solutions, suppositories, creams, ointments, injectables, auto-injector products, and other drug products.
Regulatory expertise

EpiPen^® and EpiPen^® Jr are registered trademarks of Mylan Inc. licensed exclusively to its wholly-owned subsidiary, Dey Pharma, L.P. of Basking Ridge, New Jersey, USA.

Cytomel is a registered trade mark of King Pharmaceuticals Research and Development, Inc. a wholly owned subsidiary of King Pharmaceuticals, Inc.